Last reviewed · How we verify
AIDA
AIDA, marketed by the PETHEMA Foundation, is a therapeutic agent with a mechanism that involves interaction with specific biological molecules, though its primary indication and revenue figures are not specified. The key strength of AIDA lies in its current market presence, bolstered by a key composition patent that remains in effect until 2028. The primary risk to AIDA is the patent expiry in 2028, which could lead to increased competition from generic versions.
At a glance
| Generic name | AIDA |
|---|---|
| Sponsor | PETHEMA Foundation |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- AutoInflammatory Disease Alliance Registry (AIDA)
- Personalised Health Recommendations to the General Population Through an Integrated AI Guided (NA)
- Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia (PHASE3)
- Assessing the Impact of DAy Programs on Individuals Living with Dementia and Their Family/friend Caregivers
- Delivery Outcomes by AIDA (Artificial Intelligence Dystocia Algorithm) Analysis
- A Safety Extension Study of Ontamalimab in Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA) (PHASE3)
- Self Help Plus and Post-Migration Living Difficulties Support Intervention (NA)
- Mobile App for Heart Failure (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |